New Drug Pipeline Candidate DMX-700 & Company Update
Filed with ASX · · 30 pages · English
MELBOURNE, Australia, 10 October 2019: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, today announced its next development pipeline candidate; DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The new discovery was identified using Dimerix’ proprietary Receptor-HIT assay and is one of a number of potential candidates under preliminary assessment. T
Earlier from Dimerix
- DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment
- DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited
- DMX-200 Clinical Update
- Dimerix Signs Licence Agreement for Receptor-HIT Technology
- DMX-200 Manufacturing Update
Later from Dimerix
- Dimerix Holds Pre-IND Meeting on DMX-200 With FDA
- Dimerix Completes $2.5m Placement
- DMX-200 Clinical Trial Update
- Quarterly Commentary & Appendix 4C
- Half Yearly Report and Accounts
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix